PROVO, Utah–(BUSINESS WIRE)–GeNOsys, Inc. (OTCBB: GNYS – News) today announced they are sponsoring a Phase I safety trial in collaboration with Nitric Solutions Inc. GeNOsys will be testing their patented nitric oxide generator and nitric oxide producing formula for safety and effectiveness in treating disease. In a parallel study Nitric Solutions will be testing the efficacy of their prophilactic nitric oxide producing formula NitrisolTM. The studies will be conducted in a Canadian government research facility by Dr. Kevin Kane; results are expected to be available within 30 days. GeNOsys will demonstrate that nitric oxide can be safely administered with the generator in compliance with FDA guidelines. Nitric Solutions Inc. will show the antimicrobial effectiveness of NitrisolTM in the treatment of H1N1.
“We are pleased to join Nitric Solutions in this study because it accelerates our timeline,” stated Mr. John W.R. Miller, Chairman of the Board. “This study accomplishes a key milestone in our product development plan. The information obtained will demonstrate the safety of our generator and establish the legitimacy of its bedside use. This study will allow GeNOsys to participate in the Phase II human clinical trial evaluating the therapeutic use of gaseous nitric oxide which is scheduled by Dr. Kevin Kane to begin this fall.”
About GeNOsys:
GeNOsys, Inc. (generated nitric oxide systems) is a medical research and development company specializing in pharmaceutical, biotechnical and medical gas generating systems. Nitric oxide gas will be one of the medical gases that will be generated along with various combinations of beneficial medical gases suitable for the control of human disease. Distribution will be accelerated through the use of already existing distribution networks that currently sell related respiratory products. For further information, see the Company’s Website at: www.genosysusa.com.
About Nitric Solutions:
Nitric Solutions Inc. (NSI) is a privately owned Canadian research and development corporation dedicated to developing new therapies and technologies to utilize the beneficial effects of nitric oxide in human and veterinary medicine. NSI works with Care Fusion Inc. (formerly Cardinal Health), Nitric Bio Therapeutics Inc., GeNOsys Inc., and others to accomplish this. For further information, see the Company’s Website at: www.nitricsolutions.com.
This press release may contain forward-looking statements including the Company’s beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associated with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company’s filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speak only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.